Kymera Therapeutics, Inc. Announces Commencement of Public Offering
Kymera Therapeutics, Inc. has announced the commencement of an underwritten public offering of $250.0 million of shares of its common stock and pre-funded warrants to purchase shares of its common stock. Its pipeline of preclinical and clinical degrader programs is designed to address large patient populations with significant need and clear commercial opportunity. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The company is a clinical-stage biopharmaceutical company that is advancing a new class of small molecule medicines using targeted protein degradation (TPD). Kymera is focused on developing medicines that address critical health problems and have the potential to dramatically improve patients’ lives. The company’s TPD approach allows them to target disease targets and pathways that are inaccessible with conventional therapeutics.
Kymera is also making progress in their degrader oncology programs, which target undrugged or poorly drugged proteins to create new ways to treat cancer. The company’s commitment to continued growth and innovation in the biopharmaceutical industry is evident through its focus on building its pipeline, research and development capabilities, and its intellectual property position. This demonstrates the company’s dedication to providing cutting-edge treatments for patients in need.
The securities described above are being offered pursuant to an automatically effective shelf registration statement on Form S-3 (No. 333-259955) that was filed with the US Securities and Exchange Commission (the “SEC”) on October 1, 2021. This offering is being made only by means of a prospectus supplement and an accompanying prospectus that form a part of the registration statement.
Kymera Therapeutics, Inc has announced the commencement of a public offering of $250.0 million of shares of its common stock and pre-funded warrants to purchase shares of its common stock. The company’s TPD approach allows them to target disease targets and pathways that are inaccessible with conventional therapeutics, making it an attractive choice for those seeking innovative and effective treatments for cancer and immunological diseases.
